Vical edges closer to the data that count

With investors passively waiting for biotech companies to produce definitive data for gene therapy, Vical Inc. has finally reached the pivotal threshold with its Allovectin-7 for metastatic melanoma.

VICL has designed two open-label trials - one an expanded Phase II trial and the other a Phase III trial in a population the company has not investigated before - each of which is intended to support a submission to the FDA. The company has not asked for Fast Track designation for Allovectin-7...